TY - JOUR
T1 - Biglycan neo-epitope (BGN(262)), a novel biomarker for screening early changes in equine osteoarthritic subchondral bone
AU - Adepu, Saritha
AU - Ekman, Stina
AU - Leth, Jakob
AU - Johansson, Ulrika
AU - Lindahl, A.
AU - Skiöldebrand, Eva
PY - 2022
Y1 - 2022
N2 - Objective: Native biglycan (BGN), which can undergo proteolytic cleavage in pathological conditions, is well known to be involved in bone formation and mineralization. This study aimed to delineate the specific cleavage fragment, a neo-epitope for BGN (BGN(262)), in synovial fluid (SF) from young racehorses in training, osteoarthritic (OA) joints with subchondral bone sclerosis (SCBS), and chip fracture joints.Design: A custom-made inhibition ELISA was developed to quantify BGN(262) in SF. Cohort 1: A longitudinal study comprising 10 racehorses undergoing long-term training. Cohort 2: A cross-sectional study comprising joints from horses (N = 69) with different stages of OA and radiographically classified SCBS. Cohort 3: A cross-sectional study comprising horses (N = 9) with chip fractures. Receiver operating characteristic (ROC) curve analysis was performed (healthy joints vs chip joints) to evaluate BGN(262) robustness.Results: Cohort 1: SF BGN(262) levels from racehorses showed a statistical increase during the first 6 months of the training period. Cohort 2: BGN(262) levels were significantly higher in the SF from severe SCBS joints. Cohort 3: SF BGN(262) levels in chip fracture joints showed a significant increase compared to normal joints. The ROC analysis showed an AUC of 0.957 (95% C.I 0.868-1.046), indicating good separation between the groups.Conclusions: The data presented show that BGN(262) levels increase in SF in correlation with the initiation of training, severity of SCBS, and presence of chip fractures. This suggests that BGN262 is a potential predictor and a novel biomarker for early changes in subchondral bone (SCB), aiming to prevent catastrophic injuries in racehorses. (c) 2022 The Author(s). Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International. This is an open access article under the CC BY license (http://creativecommons.org/ licenses/by/4.0/).
AB - Objective: Native biglycan (BGN), which can undergo proteolytic cleavage in pathological conditions, is well known to be involved in bone formation and mineralization. This study aimed to delineate the specific cleavage fragment, a neo-epitope for BGN (BGN(262)), in synovial fluid (SF) from young racehorses in training, osteoarthritic (OA) joints with subchondral bone sclerosis (SCBS), and chip fracture joints.Design: A custom-made inhibition ELISA was developed to quantify BGN(262) in SF. Cohort 1: A longitudinal study comprising 10 racehorses undergoing long-term training. Cohort 2: A cross-sectional study comprising joints from horses (N = 69) with different stages of OA and radiographically classified SCBS. Cohort 3: A cross-sectional study comprising horses (N = 9) with chip fractures. Receiver operating characteristic (ROC) curve analysis was performed (healthy joints vs chip joints) to evaluate BGN(262) robustness.Results: Cohort 1: SF BGN(262) levels from racehorses showed a statistical increase during the first 6 months of the training period. Cohort 2: BGN(262) levels were significantly higher in the SF from severe SCBS joints. Cohort 3: SF BGN(262) levels in chip fracture joints showed a significant increase compared to normal joints. The ROC analysis showed an AUC of 0.957 (95% C.I 0.868-1.046), indicating good separation between the groups.Conclusions: The data presented show that BGN(262) levels increase in SF in correlation with the initiation of training, severity of SCBS, and presence of chip fractures. This suggests that BGN262 is a potential predictor and a novel biomarker for early changes in subchondral bone (SCB), aiming to prevent catastrophic injuries in racehorses. (c) 2022 The Author(s). Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International. This is an open access article under the CC BY license (http://creativecommons.org/ licenses/by/4.0/).
KW - Biglycan neo-epitope
KW - Subchondral bone sclerosis
KW - Osteoarthritis
KW - Chip fractures
KW - Race horses
KW - Biglycan neo-epitope
KW - Subchondral bone sclerosis
KW - Osteoarthritis
KW - Chip fractures
KW - Race horses
UR - https://res.slu.se/id/publ/119331
U2 - 10.1016/j.joca.2022.07.005
DO - 10.1016/j.joca.2022.07.005
M3 - Journal article
SN - 1063-4584
VL - 30
SP - 1328
EP - 1336
JO - Osteoarthritis and Cartilage
JF - Osteoarthritis and Cartilage
IS - 10
ER -